Time & Date: 2 September, 12:15 – 13:15 CEST
Chairpersons: J.F. Korobelnik ITALY & R. Guymer AUSTRALIA
Speakers & Presentations:
J.F. Korobelnik ITALY
12:15 Welcome
T. Jackson UK
12:17 Results of Part A of KALAHARI, a Phase 2 Trial of THR-149, a plasma kallikrein (pKal) inhibitor, for the treatment of diabetic macular oedema (DMO)
J.F. Korobelnik ITALY
12:23 Personalised Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
A. Joussen GERMANY
12:29 Angiopoietin-2 Signalling and Vascular Stability With Faricimab in Diabetic Macular Edema
J. Cunha-Vaz PORTUGAL
12:35 Predicting 5-Year Progression to Vision-Threatening Complications in Patients With Diabetes Using Machine Learning
P-H. Gabrielle FRANCE
12:41 Three-Year Treatment Outcomes Of Aflibercept Versus Ranibizumab For Diabetic Macular Edema: Data From The Fight RetinalBlindness! Registry
M. Singer USA
12:47 3-Year Safety and Functional Outcomes in DME Patients treated with the 0.19 mg FAc Implant in the Phase IV, Prospective PALADIN Study
R. Guymer AUSTRALIA
12:53 VOYAGER: An Innovative, Global, Observational Study to Gain Real-world Insights Into the Long-term Utilisation of the Port Delivery System With Ranibizumab and Faricimab for the Treatment of nAMD and DME
S.D. Esposti UK
12:59 A survey of current interpretation of the National Institute for Health and Care Excellence (NICE) Guidelines for the initiation of intravitreal anti-VEGF therapy for centre-involving diabetic macular oedema (DMO) in the United Kingdom
J. Cunha-Vaz PORTUGAL
13:05 Deep Learning Model to Identify Moderately Severe and Severe Non-proliferative Diabetic Retinopathy From 7-Field Colour Fundus Photographs
All Faculty
13:11 Discussion
